PIRS News and Press, Pieris Pharmaceuticals Inc. From 03/30/21

Company To Host an Investor Conference Call on Tuesday, March 30, 2021 at 8:00 AM EDT Pieris achieves $13 million milestone from AstraZeneca for initiation of PRS-060/AZD1402 phase 2a study and AstraZeneca to purchase $10 million equity stake in Pieris common stock as part of an amende...

When it comes to penny stocks, you can’t count out volatility. Price plays a big role, and based on the definition of these stocks, even 50 cents can mean big shifts in position value. If you’re new to these cheap stocks, you may not know what I’m talking about. The d...

Pieris Pharmaceuticals (PIRS) soars 15% premarket after Seagen (SGEN) makes a strategic equity investment in the company as part of an ongoing collaboration between them.The companies have amended their existing immuno-oncology agreement around joint development and commercial right...

Seagen will supply Pieris with TUKYSA® to evaluate the drug in combination with cinrebafusp alfa (PRS-343) in gastric cancer Pieris' co-development option for one program from existing multi-target collaboration amended to US co-promotion option with increased royalties if exercis...

BOSTON, MA / ACCESSWIRE / March 23, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced ...

BOSTON, MA / ACCESSWIRE / February 23, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today anno...

The FDA has lifted partial clinical hold on Phase 1 studies evaluating Pieris Pharmaceuticals' ([[PIRS]] +3.4%) lead candidate, PRS-343. As previously guided, the Company intends to move into a proof-of-concept study of PRS-343 in gastroesophageal cancer.The FDA instituted a partial...

BOSTON, MA / ACCESSWIRE / January 19, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, tod...

Ocugen (OCGN) +127%.The9 Limited (NCTY +62% after signing a legally binding cooperation and investment term sheet.Bionano Genomics (BNGO +44% on publishing study on Autism Risk Genes.ViewRay (VRAY +23% on preliminary Q4 results.AirNet Technology (ANTE +28%&#...

Pieris Pharmaceuticals, Inc. (PIRS) Q3 2020 Results Conference Call November 04, 2020 08:00 AM ET Company Participants Tom Bures - VP, Finance Steve Yoder - President and CEO Hitto Kaufmann - Chief Scientific Officer Shane Olwill - SVP and Head, Translational Science Conference Call Participa...